---
title: "ARS Pharmaceuticals | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 33.66 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295839489.md"
datetime: "2026-08-13T20:11:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295839489.md)
  - [en](https://longbridge.com/en/news/295839489.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295839489.md)
---

# ARS Pharmaceuticals | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 33.66 M

Revenue: As of FY2026 Q2, the actual value is USD 33.66 M, beating the estimate of USD 31.32 M.

EPS: As of FY2026 Q2, the actual value is USD -0.63, missing the estimate of USD -0.4925.

EBIT: As of FY2026 Q2, the actual value is USD -60.59 M.

### Second Quarter 2026 Financial Highlights

#### Revenue

ARS Pharmaceuticals, Inc. reported total revenue of $33.7 million for the second quarter ended June 30, 2026. This included $26.2 million in net product revenue from neffy sales in the United States, $0.1 million in collaboration revenue from international partners, and $7.4 million in supply revenue from partners.

#### Operating Expenses

Total operating expenses, excluding cost of goods sold, were $82.3 million for the quarter. Selling, general and administrative (SG&A) expenses amounted to $77.6 million, while research and development (R&D) expenses were $4.7 million.

#### Net Loss

ARS Pharmaceuticals, Inc. recorded a net loss of - $62.3 million, or - $0.63 per share basic and diluted, for the second quarter of 2026.

#### Cash Position

As of June 30, 2026, ARS Pharmaceuticals, Inc. had $143.8 million in cash, cash equivalents, and short-term investments.

### Year-to-Date 2026 Financial Highlights (Six Months Ended June 30, 2026)

#### Revenue

For the six months ended June 30, 2026, total revenue was $56.339 million, comprising $43.662 million in net product revenue, $2.546 million in collaboration revenue, and $10.131 million in supply revenue.

#### Operating Expenses

Total operating expenses for the six-month period were $177.949 million, with cost of goods sold at $19.132 million, R&D expenses at $9.034 million, and SG&A expenses at $149.783 million.

#### Net Loss

ARS Pharmaceuticals, Inc. reported a net loss of - $122.957 million, or - $1.24 per share basic and diluted, for the six months ended June 30, 2026.

### Operational Metrics (neffy U.S. Commercial Metrics)

U.S. net product revenue from neffy was $26.2 million for the second quarter, contributing to $43.7 million year-to-date. Total U.S. epinephrine market share reached 5% as of the end of the second quarter of 2026, doubling from 2.5% in the same period of 2025. Market share among field-targeted accounts increased to 8%, up from 4% in the second quarter of 2025, and the company observed over 16,000 unique prescribers in the second quarter, nearly tripling the number from the same period in 2025.

### Outlook and Guidance

ARS Pharmaceuticals, Inc. expects aggregate SG&A and R&D expenses for the second half of 2026 to be between $114 million and $126 million, with cash-based expenses projected at $100 million to $110 million due to a more than 40% reduction in cash-based SG&A from the first half of 2026. The company anticipates reaching cash flow breakeven by the end of 2027 based on its revised expense plan. Additionally, interim data from the Phase 2b trial for its chronic spontaneous urticaria (CSU) program is expected in the first quarter of 2027.

### Related Stocks

- [SPRY.US](https://longbridge.com/en/quote/SPRY.US.md)

## Related News & Research

- [Hennion & Walsh Asset Management Inc. Acquires Shares of 175,614 ARS Pharmaceuticals, Inc. $SPRY](https://longbridge.com/en/news/295770946.md)
- [SPRY Deadline Alert: SueWallSt Reminds ARS Pharmaceuticals Inc. (SPRY) Investors of Securities Class Action Deadline on October 5, 2026](https://longbridge.com/en/news/295826002.md)
- [Flexsteel Q4 2026 Earnings Preview](https://longbridge.com/en/news/296031749.md)
- [20:01 ETSPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit](https://longbridge.com/en/news/296036090.md)
- [ARS Pharmaceuticals Chief Commercial Officer Margaret Ekins Smith files initial beneficial ownership statement](https://longbridge.com/en/news/296144706.md)